Oral α-secretase enhancers designed to prevent Aβ formation at every disease stage

Strengthening the brain's natural defence against amyloid

  • Protective by design

    ADAM10 cuts APP in a way that prevents amyloid-β from forming and releases neurotrophic sAPPα.

  • Small Molecule

    Designed as a once-daily pill for early and chronic treatment.

  • Genetically validated

    Human genetics links mutations in ADAM10 to Alzheimer’s.

Alzheimer's begins decades before memories fade.

Early therapeutic intervention preserves what matters most.

Our goal

Treat Alzheimer's at its origin, prior clinical symptoms, with a therapy safe enough for long-term use.

From research to the clinic

AlphaSphere is a planned biotech Spin-off from the University of Basel

Accessible treatment

A simple oral pill instead of infusions and MRI monitoring, so treatment can reach more patients.

Founding Team

Advisory Board

Dr. Ulf Neumann

Drug Development

Dr. Lutz Wevelsiep

CMC & Regulatory

Partners & Supporters

Prof. Dr. Mike Recher

Scientific Co-Founder
mike.recher@usb.ch 

Prof. Dr. Rainer Riedl

Medicinal Chemistry, ZHAW

Prof. Dr. Stefan Lichtenthaler

Alpha-Secretase KOL, DZNE

Dr. Adrian Baldrich

Dr. Florian Marquardsen

Let's talk

Investors, pharma partners, scientists or future colleagues: we look forward to hearing from you.